Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Gains from Investment Securities (2016 - 2025)

Standard Biotools (LAB) has disclosed Gains from Investment Securities for 14 consecutive years, with -$3.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Investment Securities fell 5528.57% to -$3.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$3.3 million, a 635.02% decrease, with the full-year FY2024 number at $39.2 million, up 321.92% from a year prior.
  • Gains from Investment Securities was -$3.4 million for Q3 2025 at Standard Biotools, down from $252000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $39.2 million in Q4 2024 to a low of -$6.9 million in Q4 2022.
  • A 5-year average of $2.0 million and a median of $252000.0 in 2025 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: surged 5403.7% in 2022, then tumbled 5528.57% in 2025.
  • Standard Biotools' Gains from Investment Securities stood at $972000.0 in 2021, then crashed by 812.96% to -$6.9 million in 2022, then skyrocketed by 87.58% to -$861000.0 in 2023, then soared by 4654.36% to $39.2 million in 2024, then crashed by 108.72% to -$3.4 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Gains from Investment Securities are -$3.4 million (Q3 2025), $252000.0 (Q2 2025), and -$232000.0 (Q1 2025).